Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Chemizon has announced that it has signed an agreement with Array BioPharma to provide Array with various medicinal chemistry services including chemical synthesis and new route research. Chemizon’s ...

BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Hi, good morning everybody and thank you for joining us for Day Three, our final day. Here at Annual BofA Merrill Healthcare Conference in Vegas. We are certainly excited to be able to host Array ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

BOSTON (CBS.MW) -- Shares of Array BioPharma jumped 16 percent in after-hours trading on Monday after the small biotech firm said it'll collaborate with Genentech on research into potential new cancer ...

Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...

* Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍ Source text: Further company coverage: ...